Potential risk of liver injury in epileptic patients during COVID-19 pandemic

Table 1 Drug-drug interaction between antiseizure medications and anti-coronavirus disease 2019 agents

	ATV	DRV/c	LPV/r	RDV	FAV	HCLQ/CLQ	TCZ	IFN-β-1α
Brivaracetam	Mi	-	Mi	-	-	Mo	-	-
Carbamazepine	S	S	Mo	S	-	S	Mi	Mo
Clobazam	Mo	Mo	Mo	-	-	-	-	-
Diazepam	Mo	Mo	Mo	-	-	-	-	-
Eslicarbazepine	Mo	Mo	Mo	Mo	-	Mo	-	-
Ethosuximide	Mo	Mo	Mo	-	-	-	-	-
Gabapentin	-	-	-	-	-	-	-	-
Lacosamide	Mi	Mo	Mi	-	-	-	-	-
Lamotrigine	-	Mo	Mo	-	-	-	-	-
Levetiracetam	-	-	-	-	-	-	-	-
Lorazepam	-	-	-	-	-	-	-	-
Oxcarbazepine	Mo	Mo	Mo	Mo	-	Mo	-	Mo
Perampanel	Mo	Mo	Mo	-	-	-	-	-
Phenytoin	S	S	Mo	S	-	S	Mi	Mo
Phenobarbital	S	S	Mo	S	-	S	Mi	Mo
Pregabalin	-	-	-	-	-	-	-	-
Primidone	S	S	Mo	S	-	S	Mi	-
Rufinamide	Mo	Mo	Mo	Mo	-	Mo	-	-
Topiramate	-	Mo	-	-	-	-	-	-
Valproic acid	-	Mo	Mo	-	-	-	-	Mo
Vigabatrin	-	-	-	-	-	-	-	-
Zonisamide	-	Mo	-	-	-	-	-	-

ATV: Atazanavir; DRV/c: Darunavir/cobicistat; LPV/r: Lopinavir/ritonavir; RDV: Remdesivir; FAV: Favipiravir; HCLQ/CLQ: Hydroxych- loroquine/chloroquine; TCZ: Tocilizumab; IFN-β-1α: Interferon β-1α; S: Severe interaction, medications should not be co-administered; Mo: Moderate interaction, dose adjustment or close monitoring is required; Mi: Mild interaction, the need for dose adjustment or monitoring is unlikely.